Impaired Th17 immunity in recurrent C. difficile infection is ameliorated by fecal microbial transplantation

Subjects

Study protocols were approved by Clinical Research Ethics Boards of the University of British Columbia (H15-01682, H09-01238 and H18-02553) and the Vancouver Coastal Health Authority (V15-01682). All participants were ≥18 years old and provided written informed consent. Inclusion criteria for CDI cohorts was a laboratory-confirmed C. difficile infection (CDI) diagnosed by a positive PCR assay for tcdB in the presence of diarrhea (≥ 3 loose or watery bowel movements per day for ≥ 2 consecutive days). Exclusion criteria for all cohorts were HIV infection, receipt of IVIG or rituximab within 6 months, hemorrhagic disorder precluding phlebotomy, or pregnancy. Details of cohorts are in Table 1.

New onset CDI cohort: patients with a primary incidence of CDI receiving physician-prescribed, metronidazole or vancomycin, samples collected within 5 days of diagnosis.

Recurrent CDI cohort: patients receiving assessment and/or treatment for recurrent CDI with ≥ 1 episode of CDI and ≥ 1 unprovoked recurrence of CDI (return of diarrhea within two months after successful treatment for CDI, without additional antibiotics). Blood collected prior to FMT.

FMT analysis group: subset of recurrent CDI cohort, second blood draw 8-12 weeks following FMT. FMTs were administered via a single 50 mL enema from healthy donor stool, frozen and thawed as reported ¹³ under approved UBC ethics protocols (H13-01221 and H15-00763).

IBD cohort: established diagnosis of either Crohn’s disease (CD) or ulcerative colitis (UC) and age and sex-matched healthy controls. Clinical data have been previously published ¹⁴.

Healthy controls: no previous diagnosis of CDI, immune compromise or chronic intestinal diseases/conditions.

Clinical data

A medical history was obtained from all study participants. CDI patients received phone follow ups every 14 days for 45 days, to assess for recurrent CDI (initial cessation of diarrhea, followed by recurrence within 45 days from completion of therapy and a positive stool test for C. difficile). For disease severity classification, individuals with new onset CDI were given an ATLAS score using published criteria ¹⁵. Individuals with recurrent CDI were classified as mild if they never required hospitalization. If they required hospitalization or administration of IV fluids during a CDI episode, they were defined as moderate, and if they had multiple recurrent hospitalizations they were classified as severe.

Sample collection and processing

Peripheral blood was collected into 9mL sodium heparin vacutainers (Becton-Dickinson (BD)) and transported at ambient temperature. OX40 assays were set up as described below using whole blood within 4h of collection and plasma aliquots were stored at -80°C.

Reagents

Staphylococcal enterotoxin B (SEB; Sigma-Aldrich, St. Louis, USA) was used at 1μg/mL. Pediacel®, a pentavalent vaccine containing components of pertussis vaccine, diphtheria and tetanus toxoids, inactivated poliomyelitis vaccine and Haemophilus influenzae B conjugate vaccine (Sanofi Pasteur Ltd, Lyon, France) was used at 1/40 dilution. C. difficile TcdA and TcdB toxoids (formaldehyde inactivated; List Biological Laboratories Inc. Campbell, USA) were used at 10μg/mL and 5μg/mL respectively. Soluble anti-CD3 (clone OKT3, UBC Antibody Lab, Vancouver, Canada) was used at 0.25μμg/mL. Tetanus toxoid was used at 2μg/mL (Enzo Life Sciences, Inc, Farmingdale, NY, USA).

C. difficile growth and TcdBCROPS protein production

C. difficile ATCC strain 9689 was grown on YT agar plates anaerobically for 48-72 hours at 37ºC then colonies were grown in BHI broth at 37°C in an anaerobic chamber for 24-48 hours. Genomic DNA was extracted as previously described ¹⁶ and TcdB^CROPS amplified using the following primers:

5’-GGTTCGAACTATTCACTAATCACTAATTGAGC - 3’ and

5’-CTCGGATCCTGAAGAAAATAAGGTGTCACAAG-3’.

TcdB^CROPS was expressed with a 6xHis tag in Escherichia coli BL21(DE3)PLysS and purified by metal affinity chromatography as previously described ¹⁷.

Identification of antigen-specific T cells using the OX40 assay

The OX40 assay was performed as previously described ¹⁴. OX40 assay mAb panel is listed in Supplemental Table 1. A four-laser LSRII FortessaX20 flow cytometer (BD) was used for data acquisition, utilising application settings. Assay cut offs were >0.02% of CD4⁺ T cells (being the mean ± 3SD of unstimulated wells) and consisting of at least 20 cells. Analysis was performed using FlowJo software (v10.6.1 Treestar Inc, Ashland, USA). IBD cohort data analysis used the DownSample v3.0.0 plugin to generate populations of 100 cells from CD25⁺OX40⁺ populations, which were then concatenated and analysed using tSNE v2.0 ¹⁸ and FlowSOM v1.5 ¹⁹ plugins.

Cytokine analysis

Cell supernatants were collected following either cell growth of 5h stimulation with 10ng/mL phorbol 12-myristate 13-acetate (PMA) and 500ng/mL ionomycin in presence of 10μg/mL Brefeldin A (Signa-Aldrich). Concentrations of secreted cytokines in cell supernatants were measured using the 13-plex Th cytokine bead array kit according to manufacturer’s directions (BioLegend). CBA data were acquired on a 3-laser Cytoflex cytometer (Beckman Coulter) and analyzed using FCAP array v3 software (BD).

ELISA

Quantification of anti-TcdA, TcdB IgG and IgA levels in plasma was performed by ELISA as previously described ¹⁴, using plates coated with 1μg/mL of TcdA or TcdB toxoids from List Biological Laboratories Inc (Campbell, CA, USA) or 1/100 dilution of Pediacel. Levels of anti-TcdB^CROPS IgG and IgA were measured by ELISA using 1μg/mL. A standard made from pooled plasma samples from subjects in our cohorts with high-titre antibodies was included with each ELISA and used to generate relative arbitrary units (AU) for cross-assay standardization.

Isolation of TcdB-specific CD4⁺ T cells

Approximately 30mL of peripheral blood was centrifuged at 500 x g for 15min with brake off and 5mL of the buffy coat layer collected. This was mixed with 3mL Iscove’s Modified Dulbecco’s Medium (Thermo Fisher Scientific, Waltham, USA) and 4mL plated per well in a 6-well tissue culture plate (BD) and stimulated with 5μg/mL TcdB for 40-48h. CD4⁺ T cells were isolated using the CD4⁺ RosetteSep enrichment cocktail (STEMCELL Technologies) and TcdB-specific live CD4⁺CD25⁺OX40⁺ were isolated using a four-laser FACSAria IIu cell sorter (BD) to >95% purity.

T cell expansion

Sorted cells were expanded with autologous APCs and antigen (or soluble anti-CD3) in presence of 200U/mL IL2 (Proleukin). APCs were obtained from PBMCs by negative isolation with CD3⁺ EasySep kit (Miltenyi Biotec) and irradiated 25Gy. Irradiated APCs were plated at 1 x 10⁵ cells/well in U-bottom 96 well plates and 20,000 sorted CD4⁺ T cells added. Antigens were added at specified concentrations and cells incubated at 37°C (5% CO²). T cells were restimulated every 14 days. Culture media for all T cell culture experiments was X-VIVO 15 (Lonza) supplemented with 5% heat-inactivated human serum (NorthBio Inc, Toronto, Canada), 1% Glutamax and 1% Penicillin-Streptomycin (Invitrogen). Cell proliferation was measured by staining with 5μM Cell Proliferation Dye eF450 (Invitrogen).

HLA typing and TCR sequencing

HLA typing of the HLA-DRB1 locus was performed to a 4-digit resolution using sequence-specific oligonucleotide (SSO) typing by the Immunology Laboratory at Vancouver General Hospital. For TCR sequencing, DNA was extracted from isolated TcdB-specific CD4⁺ cells using QIAmp DNA mini kit according to manufacturers’ instructions (Qiagen). TCR sequencing of the beta chain was performed by Adaptive Biotechnologies (Seattle, USA) and analyzed using their online immunoSEQ analyzer software.

Tetramer guided epitope mapping

Epitope mapping was performed as previously described 20 to identify HLA-DRB-restricted peptide epitopes within the CROPS domain of C. difficile toxin B (UniProt ID: P18177, amino acid positions 1831 – 2366) using a peptide library of 20mers overlapping by 12 amino acids (total of 66 peptides, Mimotopes, Australia). MP63, an influenza (flu) epitope, was used as a positive control tetramer ²¹. Briefly, PBMCs were stimulated with pools of 5 consecutive and overlapping peptides per well. After 14 days cells were stained with PE-conjugated patient-specific HLA-DRB1 tetramers loaded with a mix of the peptides from each pool. Cultures showing positive tetramer staining were further stained and analyzed with tetramers loaded with individual peptides to reveal the single peptide(s) recognized within the pool.

Statistics

Statistical analyses between 2 groups used Mann-Whitney U test or, for paired samples, Wilcoxon signed rank test. Analysis of ≥ 3 groups used Kruskal-Wallis one-way ANOVA or, for paired samples, a Friedman one-way ANOVA with Dunn’s multiple comparison post-test. Correlation analyses calculated Spearman’s rho (r). P values were considered significant when < 0.05. Prism v8 (GraphPad Software Inc) was used for all statistical analyses. Error bars represent median ± interquartile range; *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, ***p ≤ 0.0001 and ns = not significant.

Levels of C. difficile toxin-specific IgG do not distinguish infection from colonization

Studies of immunity to C. difficile have mostly focused on quantifying anti-toxin antibodies ²². Therefore, we asked whether plasma levels of anti-toxin antibodies could discriminate between healthy controls and recurrent or new onset CDI patients. ELISAs were used to measure TcdA and TcdB-specific IgG and IgA. We also measured antibodies specific for the C-terminal combined repetitive oligopeptides (CROPs) domain of TcdB (TcdB^CROPS). This region is required for receptor binding and is the target of neutralizing antibodies ²³. In all cohorts, levels of anti-TcdA IgG and IgA antibodies were significantly higher than anti-TcdB or anti-TcdB^CROPS (Supplemental Figure 1). When comparing between cohorts, only anti-TcdB IgA levels were significantly enriched in CDI patients (both recurring and new onset) compared to healthy controls (Figure 1A).

• Download figure
• Open in new tab

Figure 1. Anti-TcdB IgA responses but not IgG are elevated in CDI patients

(A) ELISAs were performed with plasma to assess levels of anti-TcdA, TcdB and TcdB^CROPS IgG and IgA for n=21 controls, n=32 recurring and n=21 new onset patients. Results are shown comparing levels of IgG (top row) and IgA (bottom row) between patient groups, using pooled high-titre plasma as internal control to obtain arbitrary units for comparison across samples. Kruskal-Wallis tests were performed. (B) Anti-TcdB and TcdA IgA and IgG levels did not correlate with ATLAS score in new onset patients (n=19; Spearman’s correlation). (C) Anti-TcdB IgG and IgA levels in recurrent patients with a history of mild (n=12) or moderate-severe illness (n=16; Mann-Whitney U tests).

We next asked if there was an association between antibody levels and disease severity. In the new onset cohort we used the ATLAS (Age, Treatment, Leukocyte count, serum Albumin, Serum creatinine) score as a measure of disease severity ¹⁵, and for the recurrent CDI cohort disease severity was determined using disease course (see methods). We found no associations with disease severity and antibody levels in either cohort (Figure 1B-C).

Patients with active C. difficile infection have circulating toxin-specific CD4⁺ T cells

Having found that the magnitude of anti-toxin antibodies were not good indicators of disease, we utilized an antigen-induced marker assay, the ‘OX40 assay’ to quantify antigen-specific CD4⁺ T cells. This assay does not require knowledge of epitopes or HLA-restriction ^24–26. Unfractionated peripheral blood was incubated with TcdA or TcdB toxoids from C. difficile ATTC strain 43255 for 44h and antigen-specific CD4⁺ T cells identified by induced co-expression of CD25 and OX40. Stimulation with Pediacel^?, a pentavalent vaccine used in childhood vaccination, served as a positive control for antigen-specific T cell activation. Representative data from a subject with recurrent CDI are shown in Figure 2A, showing that induced-expression of CD25⁺OX40⁺ CD4⁺ T cells is detectable upon TcdA or TcdB stimulation.

• Download figure
• Open in new tab

Figure 2. Proportions of anti-TcdA and TcdB CD4⁺ T cells increase with C. difficile infection

(A) Gating strategy for whole blood OX40 assays, and representative responses for unstimulated wells and wells stimulated with Pediacel, TcdA and TcdB. (B) In vitro autologous proliferation assays with sorted TcdB-specific CD4⁺CD25⁺OX40⁺ and non-TcdB-specific CD4⁺CD25⁻OX40⁻ T cells, with cells either left unstimulated (n=4) or stimulated with SEB (n=3), TcdB (n=4), TcdA (n=4) or tetanus toxoid (n=2). A representative proliferation plot is shown for a TcdB-stimulated assay; Mann-Whitney U tests performed. (C) CD4⁺ T cell specific for TcdA (controls n=16; new onset n=31; recurrent n=23) or TcdB (controls n=21; new onset n=31; recurrent n=39), Kruskal-Wallis tests; correlation analysis calculated Spearman’s rho (r) between these responses in recurrent patients (n=23). (D) Pediacel-specific CD4⁺ T cells (controls n=21; new onset n=31; recurrent n=37), Kruskal-Wallis tests; correlation analysis calculated Spearman’s rho (r) between TcdB and Pediacel responses in recurrent patients (n=37). (E) Proportions of TcdB and TcdA-specific CD4+ T cells correlated with ATLAS score in new onset patients (n=28); Spearman’s correlation; and (F) Proportions of TcdA and TcdB specific CD4+ T cells in recurrent patients with mild (n=18) or moderate-severe symptoms (n=21; Mann-Whitney U tests).

To confirm antigen specificity, CD25⁺OX40⁺ and CD25⁻OX40⁻ CD4⁺ T cells were sorted from TcdB-stimulated samples and re-stimulated with the super-antigen staphylococcus enterotoxin B (SEB; positive control), TcdB, TcdA, or tetanus toxoid from Clostridium tetani. Both cell populations proliferated in response to non-specific stimulation with SEB, but only the CD25⁺OX40⁺ cells proliferated in response to TcdB with some cross-reactivity to TcdA, and a small amount of proliferation to tetanus toxoid (Figure 2B).

To study the CD4⁺ T cell response to C. difficile toxoids in health versus CDI, we examined responses in our three cohorts (healthy controls, new onset CDI, and recurrent CDI). We found that the majority of healthy controls had detectable TcdB, but not TcdA, specific CD4⁺ T cells, and the proportion of these cells increased in both new onset and recurrent CDI. In 18/30 recurrent CDI patients, >1% of circulating CD4⁺ T cells were TcdB-specific, and there was a strong positive correlation between the presence of TcdB and TcdA-specific cells (Figure 2C). In contrast, there were no differences in the frequency of Pediacel-specific CD4⁺ T cells between the groups and no correlation between the presence of TcdB and Pediacel-specific CD4⁺ T cells (Figure 2D). These results indicate the increase in TcdA and TcdB-reactive CD4⁺ T cells is antigen and disease-specific.

We next asked whether the frequency of toxin-specific CD4⁺ T cells correlated with disease severity. We found no correlation between the ATLAS score and frequencies of TcdA or TcdB-specific CD4⁺ T cells in the new onset cohort (Figure 2E). For the recurrent CDI cohort, the frequency of TcdA, and to a greater extent, TcdB-specific CD4⁺ T cells was significantly higher in patients with moderate-severe disease, compared to those with mild disease (Figure 2F). Although TcdB-specific CD4⁺ T cells are present in most individuals, their frequency is significantly increased with repeated and more severe C. difficile infection. Thus, toxin-specific CD4⁺ T cells, but not antibodies, may be a useful biomarker of disease severity.

Subjects with recurring CDI have a reduced frequency of TcdB-specific CD4⁺ Th17 cells

Having shown that TcdB-specific CD4⁺ T cells are readily detected in peripheral blood, we next examined their phenotype in more detail to quantify proportions of Th1, Th2, Th17 and Th17.1 cells on the basis of characteristic chemokine receptor expression (Figure 3A). We found that TcdB-specific CD4⁺ T cells were enriched for Th17 cells and that the proportion of Th17 cells was specifically reduced in patients with recurring CDI (Figure 3B). This reduction in Th17 cells in recurrent CDI subjects was unique to TcdB as no differences in T cell phenotype/proportions were observed in response to the vaccine antigen Pediacel (Figure 3B).

• Download figure
• Open in new tab

Figure 3. TcdB-specific CD4⁺ T cells are enriched for Th17 cells, which are reduced in recurrent infection

(A) Gating strategy for phenotypic analysis of TcdB-specific CD4⁺CD25⁺OX40⁺ T cells. (B) Comparison of proportions of Th1, Th2, Th17 and Th17.1 cells within TcdB or Pediacel-specific CD4⁺ T cells in recurrent versus new onset CDI patients. Kruskal-Wallis tests were performed. (C) Cytokine secretion of sorted TcdB-specific CD4⁺CD25⁺OX40⁺ and non-TcdB-specific CD4⁺CD25⁻OX40⁻ T cells following PMA/Ionomycin stimulation (n=6 recurrent CDI patients). (D) Sorted cells from (C) were expanded with autologous presentation of TcdB for 5d; representative staining (from n=3) shown of CD161 expression and IL17A secretion following addition of brefeldin A. Amounts of cytokine in supernatant were measured from wells without brefeldin A added, n=2.

To confirm the functional bias towards Th17 cells, CD25⁺OX40⁺ and CD25⁻OX40⁻ CD4⁺ T cells were sorted from TcdB-stimulated samples, re-stimulated with PMA and ionomycin, and secreted cytokines analysed. Consistent with the cell surface phenotype data, TcdB-specific CD25⁺OX40⁺ cells secreted significantly higher levels of the Th17 cell-associated cytokines IL10, IL17A, IL17F and IL22 compared to CD25⁻OX40⁻ CD4⁺ T cells (Figure 3C). In contrast, there were no differences in levels of the Th1 cell cytokine IFNγ, or the Th2 cytokines IL4 and IL13. The Th17-bias of TcdB-specific CD4⁺ T cells was further confirmed by intracellular cytokine staining following in vitro expansion showing these cells expressed more of the Th17 cell marker CD161 and secreted more IFNγ IL10. IL17A, IL17F and IL22 compared to CD25⁻OX40⁻ CD4⁺ T cells (Figure 3D). Thus, TcdB-specific CD4⁺ T cells are enriched for Th17 cells and their reduced proportions in patients with recurrent CDI suggests they are important for protective immunity. TcdB-specific Th17 cells also appear to be enriched for IL17A⁺IFNγ⁺ cells, a subset previously shown to be induced by fungal and bacterial pathogens ^27,28.

IBD patients with no history of CDI have TcdB-specific CD4⁺ T cells with an altered phenotype

Individuals with inflammatory bowel disease are at increased risk for CDI and experience more severe and recurrent disease ²⁹, so we examined whether they may have underlying alterations in TcdB-specific CD4⁺ T cells. Blood was collected from a cohort of age- and sex-matched healthy controls, Crohn’s disease (CD) and ulcerative colitis (UC) patients. Clinical data for this cohort have been previously published ¹⁴; one UC subject with a recorded positive laboratory PCR test for C. difficile was excluded. We previously reported that T cell responses to Pediacel in both CD and UC patients were significantly reduced compared to healthy controls ¹⁴; therefore the frequency of TcdB-specific CD4⁺ T cells was normalized to account for the overall reduction in T cell memory responses in IBD patients. Upon normalization, we found the proportions of TcdB-specific CD4⁺ T cells were significantly higher in CD and UC patients compared to healthy controls (Figure 4A). We also observed a slight negative correlation with Harvey-Bradshaw index and the proportion of Integrin β7⁺ TcdB-specific CD4⁺ T cells, indicating that milder symptoms were associated with a higher proportion of gut homing TcdB-specific T cells in peripheral blood (Figure 4B).

• Download figure
• Open in new tab

Figure 4. IBD patients have diminished proportions of Th17 TcdB-specific CD4⁺ T cells

TcdB and pediacel-specific CD4⁺ T cells were quantified in Crohn’s disease (CD, n=20), ulcerative colitis (UC, n=19) and healthy controls (HC, n=20). (A) TcdB responses were normalised as a percent of the Pediacel response. (B) Spearman’s rho correlation analysis between Harvey-Bradshaw index and the proportion of integrin β7⁺ TcdB-specific CD4⁺ T cells (n=28). (C) The proportion of Th1, Th2, Th17 and Th17.1 cells within TcdB-specific CD4⁺ T cells was measured using flow cytometry and the gating strategy in Figure 3. (D) Data from C were analyzed using unbiased clustering analysis using FlowSOM. Two clusters of TcdB-specific CD4+ T cells were found that discriminated between patient groups; clusters are shown overlaid on a tSNE plot. Frequencies of each identified cluster were confirmed by hierarchical gating within the TcdB-specific T cell gate, with proportions shown for all groups. Kruskal-Wallis tests were performed. (E) ELISA was used to measure the levels of anti-TcdB and -TcdB^CROPS IgG and IgA in all groups.

Similar to our findings in recurrent CDI patients, the proportion of TcdB-specific Th17 cells was decreased in both CD and UC patients compared to healthy controls (Figure 4C). There was also a significant increase in the proportions of Th1 cells in UC patients compared to healthy controls, but no differences in proportions of Th2 or Th17.1 cells. Dysfunctional TcdB-specific Th17 cell responses were further confirmed by FlowSOM unbiased clustering analysis. Within TcdB-specific cells, we found two clusters both expressing the Th17-associated marker CCR6 with proportional differences between IBD patients and healthy controls (Figure 4D). Cluster I expressed CCR6 and the co-inhibitory receptor TIGIT (T cell immunoreceptor with Ig and ITIM domains), and cluster II expressed CCR6 and integrin β7. Both these TcdB-specific Th17 cell sub-populations were significantly decreased in CD patients compared to healthy controls (Figure 4D).

Interestingly, there was no difference in the levels of anti-TcdB or anti-TcdB^CROPS IgG or IgA between IBD patients and controls (Figure 4E), further confirming the importance of measuring the frequency and phenotype of TcdB-specific CD4⁺ T cells rather than antibodies to measure immunity to C. difficile.

The TcdB-specific TCR repertoire is polyclonal and includes HLA-DR7-restricted epitopes

A diverse TCR repertoire is important for effective immunity ³⁰, but chronic antigen exposure, for example through reinfections, can narrow the repertoire ³¹. We investigated whether there was evidence of TCR repertoire bias, clonal expansion and/or public clonotypes within TcdB-specific CD4⁺ T cells by TCR variable β chain repertoire sequencing of sorted TcdB-specific CD4⁺ T cells for n = 5 recurrent CDI patients. All clonotype analysis used amino acid sequences. We found that TcdB-specific CD4⁺ T cells were polyclonal: > 75% of all productively rearranged templates had a unique clonotype and the Simpsons’ clonality index was < 0.03, indicating a low frequency of identical clonotypes (Figure 5A). The polyclonality of these responses was further illustrated by analysis of the Jaccard similarity index (100% overlap would be an index of 1, Figure 5B). We found several clonotypes were present in at least two individuals, possibly representing public clonotypes (Figure 5B). There was no bias in TCR beta chain variable region (TRBV) usage (Figure 5C).

• Download figure
• Open in new tab

Figure 5. TcdB-specific CD4⁺ T cells are polyclonal TCR and include specificity for epitopes from TcdB^CROPS

TcdB-specific CD4⁺ T cells were sorted from OX40 assays for n=5 recurrent CDI patients. The TCR repertoire was assessed by sequencing the beta chain. (A) The total productive templates sequenced, the percent that were unique clonotypes and the resulting Simpson’s clonality index are shown. (B) The similarity of samples was assessed using the Jaccard similarity index, with each dot representing a unique TCR clonotype. (C) The usage frequency of TRBV family gene segments is shown. (D) Tetramer-guided epitope mapping was used to identify HLA-DRB-restricted epitopes using peptide pools from the TcdB^CROPS region. Responses to the HLA-DRB1*07:01-restricted peptides 37, 38 and 64 were detected in n=2 recurring CDI patients.

To better define T cell epitopes, a peptide pool of 15mers overlapping by 12 amino acids from the TcdB ^CROPS domain was used for tetramer-guided mapping in HLA-DRB1*07:01-positive individuals. CD4⁺ T cells specific for three peptides (5’-3’): peptide 37 ‘VGFVTINDKVFYFSDSGIIE’ (aa2119 – 2138); peptide 38 ‘KVFYFSDSGIIESGVQNIDD’ (aa2127 – 2146); and peptide 64 ‘FTDEYIAATGSVIIDGEEYY’ (aa2335-2354) were detected in two subjects (Figure 5D). These epitopes may represent key immunogenic regions of TcdB and their discovery enables tetramer-based analysis of TcdB-specific CD4⁺ T cells in future studies. Tetramer based analysis may be particularly useful to detect functionally impaired or exhausted T cells, since such cells might not upregulate activation markers as efficiently.

Fecal microbiota transplant increases TcdB-specific Th17 cells and antibodies

Some recurring CDI patients require FMT to cure infection, but how this treatment affects immunity to C. difficile was unknown. Blood from subjects with recurrent CDI was collected immediately prior to, and 8-12 weeks post, FMT. Clinical data showed that FMT was curative for 20/22 patients, as defined by absence of CDI recurrence without vancomycin prophylaxis for 3 months after FMT. T cell and antibody responses in the two patients who did not respond to FMT did not look different to the remainder of the cohort. Although the overall frequency of TcdB-specific CD4⁺ T cells was not altered by FMT, there was a significant increase in the proportion of TcdB-specific Th17 cells, and a small parallel decrease in Th2 cells (Figure 6A). Interestingly, there was a significant reduction in the frequency of Pediacel-specific CD4⁺ T cells post FMT, but no changes in the Th cell subsets proportions of these cells (Figure 6B). To rule out a global inhibition of T cell activation, we analysed responses to the super-antigen SEB. We found no change in frequency or phenotype of CD4⁺ T cells stimulated by SEB, supporting that changes in T cell frequency/function post-FMT are unique to their cognate antigen (Supplemental Figure 2).

• Download figure
• Open in new tab

Figure 6. Proportions of Th17 TcdB-specific CD4⁺ T cell are increased post-FMT

Blood was collected from n=22 recurring CDI patients immediately prior to FMT and 8-12 weeks post-FMT. OX40 assays were performed and the magnitude and phenotype of responses are shown for (A) TcdB (phenotype data from n=7); and (B) Pediacel (phenotype data from for n=8). (C) Anti-TcdA, TcdB and TcdB^CROPS; and (D) anti-Pediacel IgG and IgA levels were measured by ELISA for n=19 recurring CDI patients pre and post-FMT. Wilcoxon signed rank tests were performed. In (D) healthy control (HC) median (solid line) and interquartile range (dotted lines) are shown.

We found that anti-TcdA, TcdB and TcdB^CROPS IgA and IgG levels were all significantly increased post-FMT (Figure 6C). Importantly, anti-Pediacel IgG and IgA levels did not change post-FMT (Figure 6D), indicating that changes in pre-existing vaccine-generated immunity is not a global effect and may be restricted to circulating CD4⁺ T cells. Collectively, these results indicate that the positive effects of FMT may not only be related to changes in the microbiome, but also by improving CD4⁺ T cell and antibody mediated immunity to C. difficile toxins.